[Paclitaxel (Tesu) as a single agent in the treatment of breast cancer].
OBJECTIVE
To evaluate the efficacy and the side effects of paclitaxel (Tesu) in breast cancer patients.


METHODS
Tesu was administered at 175 mg/m2(170.9-210.8 mg/m2) to 22 patients with advanced breast cancer from March to July 1995. Tesu was given once in 21 days as one cycle, and the patients recieved 1-4 cycles (median: 3 cycles) of treatment.


RESULTS
Tesu induced 3 complete responses and 11 partial responses. The duration of remission was 2-7 months (median 3.5 months). The most frequent toxicities associated with Tesu administration were leukopenia, alopecia and myalgias.


CONCLUSIONS
Tesu as a single agent is effective in the treatment of breast cancer and the side effects are tolerable.
Jiang
Z
Z
Academy of Military Medical Science, Beijing.
Song
S
S
Liu
X
X
D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel